Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
- Conditions
- Interventions
- Registration Number
- NCT06632951
- Lead Sponsor
- AbbVie
- Brief Summary
Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for participants who have recurrent disease and disease that has progressed after frontline treatment. The purpose of this study is to evaluate ...
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
- Participant has histologically or cytologically confirmed urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Mixed histologic types are allowed if urothelial (transitional cell) is the predominant histology.
- Participant has radiologically documented metastatic disease.
- Participant must have experienced radiographic progression or relapse on checkpoint inhibitor (anti-programmed cell death protein 1 [PD-1] or anti-programmed death-ligand 1 [PD-L1]) in the metastatic, adjuvant, or neo-adjuvant setting. Participant must have received at least 2 cycles of anti-PD-1 or anti-PD-L1.
- Participants eligible for platinum must have received a platinum containing regimen (cisplatin or carboplatin) in the metastatic, locally advanced, neoadjuvant, or adjuvant setting. If platinum was administered in the neoadjuvant or adjuvant setting, participant must have progressed within 6 months of completion of treatment. Platinum ineligible participants may enroll in this study without receiving a platinum containing regimen.
- Participant has at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 as determined by investigator.
- Life expectancy must be at least 3 months.
-
Participant has received more than 1 prior chemotherapy regimen for urothelial cancer in metastatic setting, including chemotherapy agents planned in comparator arm.
- Platinum based chemotherapy administered in adjuvant or neoadjuvant setting will count towards this criterion if participant progressed within 6 months of completion.
- Chemotherapy administered during concurrent chemoradiotherapy for primary cancer will not count towards this criterion.
- The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
- Antibody-drug conjugate (ADC) will not count towards this criterion.
- Participant who previously received gemcitabine in combination with platinum in metastatic setting will be eligible to receive docetaxel or paclitaxel in comparator arm.
-
Participant has received more than 1 antibody-drug conjugate (ADC) in metastatic setting.
-
Has had prior radiation therapy within 28 days prior to first dose of study drug or who has not recovered (i.e., <= Grade 1 or at baseline) from adverse events due to radiotherapy.
-
History of additional malignancy or history of prior malignancy, except for adequately treated basal or squamous skin cancer, or cervical carcinoma in situ without evidence of disease, or malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
-
Prior allogeneic stem cell or solid organ transplantation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 3: Docetaxel, Paclitaxel, or Gemcitabine Docetaxel Participants will receive docetaxel, paclitaxel, or gemcitabine, investigator's choice, as part of the approximately 3.5 years study duration. Arm 1: Livmoniplimab (Dose A) + Budigalimab Livmoniplimab Participants will receive livmoniplimab (dose A) in combination with budigalimab, as part of the approximately 3.5 years study duration. Arm 2: Livmoniplimab (Dose B) + Budigalimab Livmoniplimab Participants will receive livmoniplimab (dose B) in combination with budigalimab, as part of the approximately 3.5 years study duration. Arm 1: Livmoniplimab (Dose A) + Budigalimab Budigalimab Participants will receive livmoniplimab (dose A) in combination with budigalimab, as part of the approximately 3.5 years study duration. Arm 3: Docetaxel, Paclitaxel, or Gemcitabine Gemcitabine Participants will receive docetaxel, paclitaxel, or gemcitabine, investigator's choice, as part of the approximately 3.5 years study duration. Arm 2: Livmoniplimab (Dose B) + Budigalimab Budigalimab Participants will receive livmoniplimab (dose B) in combination with budigalimab, as part of the approximately 3.5 years study duration. Arm 3: Docetaxel, Paclitaxel, or Gemcitabine Paclitaxel Participants will receive docetaxel, paclitaxel, or gemcitabine, investigator's choice, as part of the approximately 3.5 years study duration.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to Approximately 3.5 Years OS is defined as the time measured from randomization until death from any cause.
- Secondary Outcome Measures
Name Time Method Progression-Free survival (PFS) Up to Approximately 3.5 Years PFS is defined as the time measured from randomization until the first documentation of progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by investigators or death from any cause, whichever occurs first.
Best Overall Response (BOR) per Investigator Up to Approximately 3.5 Years BOR is defined as achieving complete response (CR) or partial response (PR) according to RECIST 1.1 as determined by investigators at any time prior to subsequent anticancer therapy.
Duration of Response (DOR) per Investigator Up to Approximately 3.5 Years DOR id defined as the time from first CR/PR until the first documentation of progressive disease according to RECIST 1.1 as determined by investigators or death from any cause, whichever occurs first.
Percentage of Participants with Adverse Events (AE)s Up to Approximately 3.5 Years An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Percentage of Participants with Serious Adverse Events (SAE)s Up to Approximately 3.5 Years An SAE is defined as an AE that results in the death of the participant, threat to the participant's life, hospitalization, congenital abnormality, persistent or significant disability/incapacitation, or medical event requiring medical or surgical interventions to prevent a serious outcome.
Percentage of Participants with Treatment Emergent Adverse Events (TEAE)s Up to Approximately 3.5 Years The treatment-emergent period is defined as time from the date of the first dose of study drug up to 90 days after the date of the last dose of study drug, or the first date starting new anticancer therapy, whichever occurs earlier. TEAEs include all AEs that occurred or worsened during the treatment emergent period and all treatment related SAEs as assessed...
Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator Up to Approximately 3.5 Years Vital signs are defined as systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.
Percentage of Participants with Clinically Significant Laboratory Values Up to Approximately 3.5 Years Percentage of participants with clinically significant laboratory values (hematology, chemistry, coagulation, and urinalysis) as assessed by the investigator.
Percentage of Participants with Immune-Related Reactions as AEs of Special Interest Up to Approximately 3.5 Years An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Maximum Observed Serum Concentration (Cmax) of Livmoniplimab Up to Approximately 3.5 Years Cmax is defined as the maximum observed serum concentration of livmoniplimab.
Cmax of Budigalimab Up to Approximately 3.5 Years Cmax is defined as the maximum observed serum concentration of budigalimab.
Time to Reach Cmax (Tmax) of Livmoniplimab Up to Approximately 3.5 Years Tmax is defined as the time to reach Cmax of livmoniplimab.
Tmax of Budigalimab Up to Approximately 3.5 Years Tmax is defined as the time to reach Cmax of budigalimab.
Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab Up to Approximately 3.5 Years AUC is defined as the area under the serum concentration versus time curve of livmoniplimab.
AUC of Budigalimab Up to Approximately 3.5 Years AUC is defined as the area under the serum concentration versus time curve of budigalimab.
Clearance (CL) of Livmoniplimab Up to Approximately 3.5 Years CL is defined as the Clearance of livmoniplimab.
CL of Budigalimab Up to Approximately 3.5 Years CL is defined as the Clearance of budigalimab.
Volume of Distribution (Vd) of Livmoniplimab Up to Approximately 3.5 Years Vd is defined as the volume of distribution of livmoniplimab.
Vd of Budigalimab Up to Approximately 3.5 Years Vd is defined as the volume of distribution of budigalimab.
Incidence of Anti-Drug Antibodies (ADAs) of Livmoniplimab Up to Approximately 3.5 Years Incidence of anti-drug antibodies of livmoniplimab.
ADAs of Budigalimab Up to Approximately 3.5 Years Incidence of anti-drug antibodies of budigalimab.
Incidences of Neutralizing Anti-Drug Antibodies (nADAs) of Livmoniplimab Up to Approximately 3.5 Years Incidences of neutralizing anti-drug antibodies of livmoniplimab.
Incidences of nADAs of Budigalimab Up to Approximately 3.5 Years Incidences of neutralizing anti-drug antibodies of budigalimab.
Trial Locations
- Locations (1)
Highlands Oncology Group - Springdale /ID# 270290
🇺🇸Springdale, Arkansas, United States